Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FGEQ4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,975
Award facts
- Contract value 100% obligated
- $37,974.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $37,974.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 300 mg/2 ml syringes. The delivery order, issued on December 18, 2025, with an ultimate completion date of January 12, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award represents a single delivery order issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare operations.
DMS Pharmaceutical Group's selection demonstrates its established capability within the federal pharmaceutical supply chain, particularly for specialty biologics and complex therapeutic products. The vendor's performance across numerous prior delivery orders since October 2025 for immunologic agents, oncology treatments, and emergency medications has positioned it as a critical supplier supporting military healthcare facilities. The PPV-G GEN V contract, awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036, provides DLA with access to a comprehensive portfolio of branded and generic pharmaceuticals, biologics, and medical consumables to meet recurring defense medical supply requirements globally.
Quick answers
Who was awarded contract SPE2DR26FGEQ4?
SPE2DR26FGEQ4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 18, 2025.
How much is contract SPE2DR26FGEQ4 worth?
The government has obligated $37,975 on SPE2DR26FGEQ4.
Is contract SPE2DR26FGEQ4 an order under another contract?
Yes. SPE2DR26FGEQ4 is a delivery order under SPE2DR25D9312, an indefinite delivery contract.
Was contract SPE2DR26FGEQ4 competed?
The extent of competition for SPE2DR26FGEQ4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award